A novel approach for estimating the nationwide incidence of renal cancer by Andreas Stang et al.
EMERGING THEMES
IN EPIDEMIOLOGY
Stang and Büchel Emerging Themes in Epidemiology 2014, 11:8
http://www.ete-online.com/content/11/1/8METHODOLOGY Open AccessA novel approach for estimating the nationwide
incidence of renal cancer
Andreas Stang1,2,3*, Christian Büchel1 and Network of Epidemiologic Cancer Registries in Germany (GEKID)Abstract
Background: The aim of this study was to provide a novel approach for estimating the incidence of renal cancer in
Germany by using hospitalization data from the years 2005–2006 and to compare these estimates with incidence
rates from cancer registries.
We used nationwide hospitalization data from the years 2005–2006 including 34.2 million hospitalizations. We used
three definitions of potential incident renal cancer cases: 1) a main or secondary diagnosis of renal cancer and a
partial or total nephrectomy; 2) a main diagnosis of renal cancer and a partial or total nephrectomy; and 3) a main
diagnosis of renal cancer (without a secondary diagnosis of renal pelvis cancer) and a partial or total nephrectomy.
In addition, we used cancer registry data for comparison of rates.
Results: Hospitalization data to which definition 2 applied provided incidence rate estimates nearly identical to
those provided by the cancer registries (when the cases registered from death certificates only were excluded).
Age-standardized (European standard population) incidence rates based on hospitalization data and cancer registry
data were 15.6 per 100 000 and 15.7 per 100 000 among men and 8.0 per 100 000 and 7.6 per 100 000 among
women respectively. Cancer registry-based incidence rates were lower especially among those federal states with
an estimated completeness of registration below 90% (Berlin and Saxony-Anhalt).
Conclusions: Representative hospitalization data can be used to estimate incidence rates of renal cancer. We
propose that incidence rates can be estimated by hospitalization data if 1) the primary treatment is performed
during an in-hospital stay and 2) nearly all patients undergo a defined surgical procedure that is not repeated for
the treatment of the same cancer. Our results may be useful for countries with no or incomplete cancer registration
or for countries that use hospitalization data to provide a representative incidence of renal cancer.
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Renal cancer accounts for 3.4% of all malignancies in
Germany and is the most lethal urologic cancer [1]. The
estimated 5-year relative survival of renal cancer patients
in Germany is 74% [1]. As a rule, partial or total nephrec-
tomy is performed before any further treatment among
patients with newly diagnosed renal cancer [2]. According
to an analysis of the clinical cancer registries of the Federal
State of Brandenburg, Germany, for the years 2006
through 2010, 95.3% of all registered newly diagnosed* Correspondence: andreas.stang@uk-halle.de
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article, unless otherwise stated.renal cancers were treated by surgery within the first
6 months after diagnosis [3].
As nephrectomy is performed with general anaesthesia,
it requires hospitalization. Thus, hospitalizations including
a diagnosis of renal cancer and a partial, simple or radical
nephrectomy may indicate incident renal cancer cases.
We recently estimated the testicular cancer incidence
based on hospitalizations that included a diagnosis of tes-
ticular cancer and an orchiectomy. The results were very
much in line with incidence estimates provided by cancer
registries in Germany [4].
Several countries either have no cancer registries or have
only regional cancer registries including France, Italy, Spain,
Turkey, India, China, Japan, Thailand, Brazil, Argentina,
Chile, Colombia [5]. However, several of these countries
use DRGs (diagnosis related groups) or self-developedntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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pital reimbursement [6]. If the estimation of incidence rates
of renal cancer is possible through the use of nationwide
DRG hospitalization data, this approach would enable these
countries to provide national and regional incidence rates
despite incomplete cancer registration.
The aim of this study was to provide a novel approach
for estimating the incidence of renal cancer in Germany
by using hospitalization data from the years 2005–2006




In 2004, the DRG reimbursement system became compul-
sory for hospitals in Germany. According to the hospital
financing law, all hospitals that are reimbursed by the
DRG-system annually transfer their individual hospitalisa-
tion data to a DRG data center. Hospital stays that are re-
imbursed by the statutory accident insurance and hospital
patient care in the ambulatory setting are not included.
Furthermore, the psychiatric and psychotherapeutic de-
partments of hospitals, military hospitals, and jail hospitals
are not reimbursed by the DRG system. All hospitals that
are reimbursed by the DRG system have a strong incentive
to report their complete hospitalisation data. The German
DRG statistics are virtually a complete record of all hospi-
talizations all over Germany with only a few exceptions.
The DRG data center undertakes a plausibility check of
the data and generates a plausibility protocol that is sent
back to the corresponding hospital. Hospitals can re-
submit their corrected data files. Thereafter, the DRG
data center forwards anonymised data to the Federal
Bureau of Statistics. Based on confidentiality regulations
(Bundesstatistikgesetz, BStatG), individual hospitalisation
data are available for research purposes. Hospitalisations
are anonymized which means that patients who are hospi-
talized more than once during the study period cannot be
re-identified. By federal law, these anonymized data can be
used for scientific purposes without ethical review. We
were able to use the hospitalisation years 2005 and 2006
including 36.3 million hospitalisations overall.
For each hospitalization, one main diagnosis and up to
99 secondary or ancillary diagnoses coded by ICD-10
(International Classification of Diseases, 10th edition) can
be documented. In 2005, diagnoses were coded according
to the ICD-10-GM (International Classification of Dis-
eases, German modification) version of 2005 [7]. In 2006,
the ICD-10-GM version 2006 was used [8]. The diagnosis
that led to the hospitalization assessed at the end of the
hospitalization is defined as the main diagnosis. Up to 100
medical procedures can be coded according to German
classification of operations and procedures (OPS), a classi-
fication that represents a German version of theInternational Classification of Procedures in Medicine and
that is updated annually by the German Institute of Med-
ical Documentation and Information (DIMDI). In 2005
and 2006, the OPS versions for the years 2005 and 2006,
respectively were used [9,10].
We used three definitions of potential incident renal
cancer cases: 1) a main or secondary diagnosis of renal
cancer (ICD-10: C64) and a partial or total nephrectomy
(OPS: 5–553, 5–554); 2) a main diagnosis of renal cancer
and a partial or total nephrectomy; and 3) a main diagno-
sis of renal cancer (without a secondary diagnosis of renal
pelvis cancer) and a partial or total nephrectomy. The ex-
clusion of renal pelvis cancer in definition 3 was motivated
by the arbitrariness of cancer registration when the cancer
report of a newly diagnosed case contains information that
is too scant so that the cancer registry cannot decide
whether it is a renal cancer or a renal pelvis cancer. In this
case, both cancers are coded according and therefore
some misclassification comes up.
Hospitalizations with a diagnosis of renal cancer but
without a partial or complete nephrectomy were disre-
garded. The scientific use file of the DRG statistics also
provides data including region of residence, age at hos-
pital admission, and gender among others.
Cancer registry data
The cancer registries of Hesse and Baden-Wurttemberg
that were built up during our study period did not provide
data. The cancer registry of North Rhine-Westphalia pro-
vided incidence data only for the administrative district of
Münster. All other cancer registries including the regis-
tries from Bavaria, Bremen, Hamburg, Lower Saxony,
Rhineland-Palatinate, Schleswig-Holstein, Saarland, Berlin
and the new federal states including Mecklenburg-West
Pomerania, Brandenburg, Saxony, Saxony-Anhalt, and
Thuringia provided individual renal cancer data. We con-
sidered incidence rates derived from cancer registries with
a high completeness of registration the reference standard.
The estimation of the completeness of cancer registration
is undertaken by the Robert Koch-Institute in Berlin on a
regular basis. This procedure starts with estimating the sex-
and age-specific mortality-incidence ratios for each cancer
in the federal states with a known high completeness of
cancer registration (so-called reference pool of cancer regis-
tries). Under the assumption that the mortality-incidence
ratios are constant across regions in Germany, these ratios
and the corresponding stratum-specific mortality rates of
the cancers in other federal states in Germany are used to
estimate the expected number of incident cases in these re-
gions. The ratio of the observed to the expected number of
registered cases provides an estimate of registration com-
pleteness. To dampen the influence of random fluctuation,
the expected and observed numbers of incident cases are
modeled by log-linear regression models [11].
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The unit of analysis was the hospital admission with a
diagnosis of renal cancer and a partial or total nephrec-
tomy. We calculated crude and age-specific rates with the
midyear populations of the years 2005 and 2006 as the de-
nominators. Population data were provided by the Federal
Bureau of Statistics. For the comparison across federal
states, we standardized the rates using the European
standard population [12]. Standard errors (SEs) of the
rates were calculated by use of the binomial distribution.
As federal state-wide incidence data were not available
from cancer registries in North Rhine-Westphalia, Hesse
and Baden-Württemberg during our study period, we
excluded these states (which comprise about 42% of the
German population) from the comparison of hospitalisa-
tion data-based and cancer registry-based incidence esti-
mates to enable a one-to-one comparison between
registry and hospitalization data.
For the assessment of agreement between hospitalization
data and cancer registry data, the cases that were registered
from death certificates only (DCO) were excluded from the
cancer registry data, because such cases are likely missing
from hospital records. However, according to the EURO-
CARE study, it should be noted that DCO cases are not ne-
cessarily a random sample of all cases as their actual
survival may be much shorter than the survival of non-
DCO cases [13].
For the comparison of the number of renal cancers
registered by the cancer registries and estimated by theTable 1 Comparison of the estimated crude and age-standard




Definition 1: Main or secondary diagnosis of renal cancer,
partial or total nephrectomy
Definition 2: Main diagnosis of renal cancer, partial or total nephrectomy
Definition 3: Main diagnosis of renal cancer and no simultaneous




Definition 1: Main or secondary diagnosis of renal cancer,
partial or total nephrectomy
Definition 2: Main diagnosis of renal cancer, partial or total nephrectomy
Definition 3: Main diagnosis of renal cancer and no
simultaneous diagnosis of renal pelvis cancer,
partial or total nephrectomy
Cancer registries
Legend: Federal States of North Rhine-Westphalia, Hesse, and Baden-Württemberg
excluded from the cancer registry data.hospitalization data, we calculated the ratio of the crude
incidence estimates (cancer registry) to the estimated
crude incidence based on the hospitalization data. We
also estimated age-specific incidence estimates based on
the nationwide hospitalization data and the cancer regis-
try data of the years 2005–2006.
Results
From 2005 through 2006, 34.2 million hospitalizations
occurred overall in Germany. Of these, a total of 25 920
hospitalizations occurred with a diagnosis of renal can-
cer and partial or total nephrectomy (0.08%). After the
exclusion of people living outside Germany, homeless
patients, and patients without known place of residence
(overall n = 231), the estimated number of hospitaliza-
tions with diagnosed renal cancer and partial or total
nephrectomy from 2005 through 2006 was 25 689 (me-
dian age for men: 66 years, 10th and 90th percentile 49
and 78 years; median age for women: 69 years, 10th and
90th percentile 50 and 81 years). Among these hospitali-
zations, 93.8% had renal cancer as the main diagnosis.
The combination of a nephrectomy and a main diag-
nosis of renal cancer (definition 2) produced nationwide
incidence rate estimates that were closest to those pro-
vided by the cancer registries (hospital-based and cancer
registry-based age-standardized rates for men: 15.6 per
100 000 and 15.7 per 100,000, respectively; hospital-based
and cancer registry-based age-standardized rate for
women: 8.0 per 100 000 and 7.6 per 100 000, respectively)ized incidence rates (cases per 100 000) of renal cancer
zation data to those generated by cancer registries
ases Crude rate (per 100 000) Age-stand. rate (per 100 000)
Rate SE Rate SE
9,882 21.1 0.2 16.5 0.2
9,306 20.0 0.2 15.6 0.2
9,256 19.9 0.2 15.5 0.2
9,400 20.2 0.2 15.7 0.2
6,060 12.5 0.2 8.5 0.1
5,691 11.7 0.2 8.0 0.1
5,660 11.7 0.2 7.9 0.1
5,604 11.6 0.2 7.6 0.1
have been excluded; SE: standard error; Death certificate only (DCO) cases were
Table 2 Comparison of the estimated Federal State-specific crude incidence rates (cases per 100 000) of renal cancer in Germany from 2005 through 2006
obtained from hospitalization data to those generated by cancer registries among men






(per 100,000) without DCO
Cancer registry/hospitalization
data estimate
Def. 1 Def. 2 Def. 3 Def. 1 Def. 2 Def. 3 Cases DCO Completeness Def. 1 Def. 2 Def. 3
State N N N Rate SE Rate SE Rate SE N N % Rate SE
WEST
Schleswig-Holstein 406 372 369 14.7 0.7 13.4 0.7 13.3 0.7 407 87 91 14.7 0.7 1.00 1.10 1.11
Hamburg 265 242 239 15.6 1.0 14.2 0.9 14.1 0.9 273 10 100 16.1 1.0 1.03 1.13 1.14
Lower Saxony 1 443 1 352 1 346 18.4 0.5 17.3 0.5 17.2 0.5 1 361 215 95 17.4 0.5 0.95 1.01 1.01
Bremen 134 128 128 20.8 1.8 19.9 1.8 19.9 1.8 129 7 92 20.1 1.8 0.97 1.01 1.01
North Rhine-Westphalia 3 166 2 976 2 960 18.0 0.3 16.9 0.3 16.8 0.3
Adminsitrative District of Münster 449 91 17.5 0.8
Hesse 1 130 1 061 1 052 19.0 0.6 17.8 0.5 17.6 0.5
Rhineland-Palatina 713 673 666 17.9 0.7 16.9 0.7 16.7 0.6 726 63 100 18.2 0.7 1.02 1.08 1.09
Baden-Württemberg 1 834 1 708 1 687 17.4 0.7 16.2 0.4 16.0 0.4
Bavaria 2 312 2 167 2 154 18.9 0.4 17.8 0.4 17.6 0.4 2 238 283 100 18.3 0.4 0.97 1.03 1.04
Saarland 233 223 223 22.8 1.5 21.8 1.5 21.8 1.5 227 6 100 22.2 1.5 0.97 1.02 1.02
Berlin 593 543 540 17.9 0.7 16.4 0.7 16.3 0.7 509 58 81 15.3 0.7 0.85 0.93 0.94
EAST
Brandenburg 679 656 654 26.8 1.0 25.9 1.0 25.8 1.0 711 46 100 28.1 1.1 1.05 1.08 1.09
Mecklenburg West-Pomerania 469 429 427 27.7 1.3 25.4 1.2 25.2 1.2 449 37 97 26.5 1.3 0.96 1.04 1.05
Saxony 1 194 1 155 1 150 28.7 0.8 27.7 0.8 27.6 0.8 1 137 95 94 27.3 0.8 0.95 0.99 0.99
Saxony-Anhalt 710 675 673 29.4 1.1 28.0 1.1 27.9 1.1 549 95 72 22.8 1.0 0.78 0.81 0.82
Thuringia 731 691 687 31.8 1.2 30.1 1.1 29.9 1.1 684 57 97 29.8 1.1 0.94 0.99 1.00
Germany 9 882 9 306 9 256 21.2 0.2 20.0 0.2 19.9 0.2 9 400 1 059 20.2 0.2 0.95 1.01 1.02
Legend: Definition 1: a main or secondary diagnosis of renal cancer (ICD-10: C64) and a partial or total nephrectomy (OPS: 5–553, 5–554); definition 2: a main diagnosis of renal cancer and a partial or total nephrectomy;
definition 3: a main diagnosis of renal cancer (without a secondary diagnosis of renal pelvis cancer) and a partial or total nephrectomy; all rates are crude rates; SE: standard error of the rate; cases: only cases registered as
non-DCO; DCO: death certificate only cases; West: West Germany, East: East Germany; age standard: European Standard Population; Germany: nationwide estimates with the exception of North Rhine-Westphalia, Hesse, and




















Table 3 Comparison of the estimated Federal State-specific crude incidence rates (cases per 100 000) of renal cancer in Germany from 2005 through 2006
obtained from hospitalization data to those generated by cancer registries among women
Hospitalization data Cancer registry data Ratio of incidence estimates
Number of cases by definition Incidence rate
(per 100.000)
Incidence rate
(per 100.000) without DCO
Cancer registry/hospitalization
data estimate
Def. 1 Def. 2 Def. 3 Def. 1 Def. 2 Def. 3 Cases DCO Completeness Def. 1 Def. 2 Def. 3
State N N N Rate SE Rate SE Rate SE N N % Rate SE
WEST
Schleswig-Holstein 256 238 233 8.8 0.6 8.2 0.5 8.0 0.5 239 77 91 8.3 0.5 0.94 1.01 1.04
Hamburg 166 154 154 9.3 0.7 8.6 0.7 8.6 0.7 150 7 100 8.4 0.7 0.90 0.98 0.98
Lower Saxony 844 777 773 10.4 0.4 9.5 0.3 9.5 0.3 795 167 95 9.8 0.3 0.94 1.03 1.03
Bremen 82 79 78 12.0 1.3 11.6 1.3 11.4 1.3 79 11 92 11.6 1.3 0.97 1.00 1.02
North Rhine-Westphalia 1 959 1 818 1 808 10.6 0.2 9.8 0.2 9.8 0.2 n,a,
Adminsitrative District of Münster 232 n.a. 91 8.6 0.6
Hesse 626 597 597 10.1 0.4 9.6 0.4 9.6 0.4 n,a,
Rhineland-Palatina 432 396 394 10.4 0.5 9.6 0.5 9.5 0.5 431 59 100 10.4 0.5 1.00 1.08 1.09
Baden-Württemberg 1 032 938 931 9.4 0.3 8.6 0.3 8.5 0.3 n,a,
Bavaria 1 432 1 345 1 338 11.2 0.3 10.6 0.3 10.5 0.3 1 361 273 100 10.7 0.3 0.96 1.01 1.02
Saarland 118 115 115 10.9 1.0 10.7 1.0 10.7 1.0 107 7 100 9.9 1.0 0.91 0.93 0.93
Berlin 359 333 328 10.3 0.5 9.6 0.5 9.4 0.5 279 98 81 8.0 0.5 0.78 0.83 0.85
EAST
Brandenburg 409 385 384 15.8 0.8 14.9 0.8 14.9 0.8 418 48 100 16.2 0.8 1.03 1.09 1.09
Mecklenburg West-Pomerania 292 276 276 17.0 1.0 16.0 1.0 16.0 1.0 286 38 97 16.6 1.0 0.98 1.04 1.04
Saxony 772 742 740 17.6 0.6 16.9 0.6 16.9 0.6 708 83 94 16.2 0.6 0.92 0.96 0.96
Saxony-Anhalt 424 405 403 16.8 0.8 16.0 0.8 15.9 0.8 337 82 72 13.3 0.7 0.79 0.83 0.84
Thuringia 474 446 444 20.0 0.9 18.8 0.9 18.7 0.9 414 47 97 17.5 0.9 0.88 0.93 0.94
Germany 6 060 5 691 5 660 12.5 0.2 11.7 0.2 11.7 0.2 5 604 997 11.6 0.1 0.93 0.99 0.99
Legend: Definition 1: a main or secondary diagnosis of renal cancer (ICD-10: C64) and a partial or total nephrectomy (OPS: 5–553, 5–554); definition 2: a main diagnosis of renal cancer and a partial or total
nephrectomy; definition 3: a main diagnosis of renal cancer (without a secondary diagnosis of renal pelvis cancer) and a partial or total nephrectomy; all rates are crude rates; SE: standard error of the rate; cases: only
cases registered as non-DCO; DCO: death certificate only cases; West: West Germany, East: East Germany; age standard: European Standard Population; Germany: nationwide estimates with the exception of North
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Figure 1 Comparison of the estimated age-specific incidence rates (cases per 100 000) of renal cancer in Germany from 2005 through
2006 obtained from hospitalization data to those generated by cancer registries. Hospitalization data-based incidence rates are based on
definition 2; Circles: age-specific incidence of renal cancer based on cancer registries in Germany without North Rhine-Westphalia, Hesse, and
Baden-Württemberg; dots: corresponding age-specific incidence of renal cancer based on DRG data; Death certificate only (DCO) cases were
excluded from the cancer registry data.
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Hesse, North Rhine-Westphalia and Baden-Württemberg,
hospitalization data-based incidence rates became slightly
lower (data not shown).
We also observed nearly identical hospitalization data-
based and cancer registry-based crude rates for each fed-
eral state separately. Cancer registry-based incidence rates
were lower especially among those federal states with an
estimated completeness of registration below 90% (Berlin
and Saxony-Anhalt) (Tables 2 and 3). The nationwide age-
specific rates of the hospitalization data and cancer regis-
try data were nearly identical for ages 30 years and more
(Figure 1). The study of federal state-specific incidence age
patterns produced the same results (Figures 2 and 3).
Discussion
We found that the estimation of the incidence of renal
cancer based on hospitalization data produces incidence
rate estimates nearly identical to those based on cancer
registries with a high completeness of registration after ex-
clusion of DCO cases. The observation of lower incidence
rates from cancer registries than from hospitalization data
in the Federal State of Saxony-Anhalt and Berlin is plaus-
ible, as the cancer registries of these states are known to
have been less complete (below 90%) than the other can-
cer registries during the study period.
Several medical factors may influence the hospital-based
incidence estimates. First, patients with renal cancer might
undergo a partial nephrectomy more than once. We were
not able to identify these patients. However, this proportion
is expected to be very low because patients undergoing sur-
gery for renal cancer undergo intraoperative histological as-
sessment to verify that the complete tumor has beenremoved (so-called R0 resection). If R0 is not verified, the
surgeon increases the amount of resection until R0 is
reached during the same surgery. Therefore, a partial or
complete nephrectomy during a further hospital stay is an
unlikely event. Second, patients with metastastic renal can-
cer at primary treatment might undergo surgery for
debulking (nephrectomy for tumor reduction). However,
these patients were detected by our algorithm as we
searched for nephrectomy of any kind. Furthermore, these
patients might later undergo surgery of metastases. How-
ever, these surgeries have different procedures codes than
those for partial or total nephrectomy. Third, patients may
be too ill to undergo nephrectomy. These patients cannot
be detected by our algorithm. However, according to an
analysis of the clinical cancer registries of the Federal State
of Brandenburg, Germany, for the years 2006 through
2010, 95.3% of all registered newly diagnosed renal cancers
were treated by surgery within the first 6 months after diag-
nosis [3]. However, a part of the remaining patients
undergo later surgery (e.g. debulking). Therefore, the 4.5%
of patients who missed surgery is most likely an overesti-
mate. In addition, it is likely that some renal cancer reports
to the cancer registry of Brandenburg were false-negative
or incomplete in terms of reported surgery information.
Fourth, although a rare event, patients with a renal cancer
who underwent surgical treatment may have developed a
further renal cancer (secondary primary) during our study
period. Therefore, the proportion of patients that is missed
will be small. The age-specific comparison of incidence
based on hospitalization data and cancer registry data re-
veals that especially renal cancer patients at very high age
(85+ years) may be underdetected by the hospitalization-
based approach.
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Figure 2 Comparison of the estimated Federal State-specific age-specific incidence rates (cases per 100 000) of renal cancer in
Germany from 2005 through 2006 obtained from hospitalization data to those generated by cancer registries among men.
Hospitalization data-based incidence rates are based on definition 2; Death certificate only (DCO) cases were excluded from the cancer registry data.
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http://www.ete-online.com/content/11/1/8There are also quality-related factors that may influence
the agreement between cancer registry-based incidence rates
and hospitalization data-based incidence rates of renal can-
cer. The agreement is influenced by the recording practices
and quality of coding (diagnostic codes and procedure
codes) used for the hospital stays. Many countries in
Europe, the United States, and Australia that use DRGs or
self-developed DRG-like classification systems for hospital
reimbursement [6] have a strong financial incentive to code
diagnoses and procedures that are relevant to reimburse-
ment. Furthermore, the agreement is influenced by the de-
gree of completeness of cancer registration. As in Germany,
there are many regional cancer registries that provide inci-
dence estimates based on incomplete registration. Especially
the new federal states of Germany suffer from registration
incompleteness which explains higher incidence estimates
based on hospitalization data than on registry data.In Europe, the highest incidence rates of renal cancer are
observed in Central and Eastern Europe [14]. The higher in-
cidence of and mortality [15] from renal cancer in East than
in West Germany among both men and women has been
observed for decades and has prompted a population-based
multicenter case–control study in West and East Germany
between 1991 and 1995. The study found that substantial
exposure to metals and solvents were associated with an in-
creased risk of renal cancer [16]. The authors of that study
hypothesized that the East–west difference in renal cancer
incidence in Germany may be explained by lower techno-
logical standards of industrial production in the former
German Democratic Republic [16]. The lower incidence
rates in West Germany may explain why the hospitalization
data based incidence rate for Germany decreased when we
added the federal states of Hesse, North Rhine-Westphalia
and Baden-Württemberg, all located in West Germany.
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Figure 3 Comparison of the estimated Federal State-specific age-specific incidence rates (cases per 100 000) of renal cancer in
Germany from 2005 through 2006 obtained from hospitalization data to those generated by cancer registries among women.
Hospitalization data-based incidence rates are based on definition 2; Death certificate only (DCO) cases were excluded from the cancer
registry data.
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In conclusion, hospitalization data can be used to esti-
mate incidence rates of renal cancer. We propose that
incidence rates can be estimated by hospitalization data
if 1) the primary treatment is performed during an in-
hospital stay and 2) nearly all patients undergo a defined
surgical procedure that is not repeated for the treatment of
the same cancer. However, in contrast to cancer registries,
German hospitalization data cannot be used for estimating
histology-specific incidence rates as hospitalization data do
not include histology codes. We have provided empirical
evidence that incidence rates for testicular cancer can be
validly estimated by hospitalization data previously [4] and
for renal cancer in this report. Another cancer eligible for
this approach is gallbladder cancer that is typically treated
in-hospital by removal of the gallbladder. Our results maybe useful for countries with no or incomplete cancer regis-
tration or for countries that use hospitalization data to esti-
mate incidence of renal cancer.
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